Close Menu

People in the News

Jan 04, 2019

Paul Meister

Arbor Biotechnologies has appointed Paul Meister to its board of directors. Meister serves as CEO of Liberty Lane Partners and previously served as president of MacAndrews & Forbes, CEO of inVentiv Health (now known as Syneos Health), and chairman of the board of Thermo Fisher Scientific and vice chairman of Fisher Scientific International, prior to Fisher's merger with Thermo.

Jan 04, 2019

Christine Tsingos

Christine Tsingos intends to retire as Executive Vice President and Chief Financial Officer of Bio-Rad, effective April 30, 2019. She has served as CFO for 16 years, during which time the company increased its revenues more than 240 percent and saw an appreciation in its stock price from approximately $30 to a recent high of more than $300 per share. Tsingos will remain in her current role through April 30, and will assist in the transition to a successor.

Jan 03, 2019

Clinton Musil

Clinton Musil has been appointed as chief business officer of Personalis, where he will initially focus on financing strategy. He joins the company from ARMO Biosciences. Prior to that, he was a managing director at Hercules Capital. Musil holds an MBA from Harvard Business School and a BS in molecular and cellular biology from the University of Arizona.

Jan 03, 2019

James Angus McDonald, Tim Cowper

James Angus McDonald has left the board of directors of Oxford Nanopore Technologies as well as the board of its daughter companies, the Genome Foundry and Metrichor, effective Dec. 13, 2018. He had been a director for Oxford Nanopore since 2010, for Metrichor since 2013, and for the Genome Foundry since 2015. McDonald was immediately replaced as director of all three companies by Tim Cowper, Oxford Nanopore's vice president of finance. Cowper joined the firm in 2012 and oversees its financial team and strategic supply chain operations. In addition, in November 2018, he was appointed as director of Oxford Nanopore Manufacturing, a new daughter company.

Jan 03, 2019

Betsy Hanna

Clinical Genomics has appointed Betsy Hanna as its president and CEO. In addition, she will join the firm's board of directors. Hanna succeeds Lawrence LaPointe as CEO, who will transition to the new role of chief innovation officer and serve as an advisor to the board. Hanna previously served as Clinical Genomics' chief commercial officer. Before that, she served as president and COO at Origin. Prior to Origin, Hanna held leadership positions at Johnson & Johnson Diagnostics, where she served as VP, strategic marketing as well as VP Europe, Mideast and Africa. 

Jan 03, 2019

Mike Guerra

California Life Sciences Association has appointed Mike Guerra as its CEO and president, effective January 7th. He will succeed Sara Radcliffe, who will be departing the firm to pursue new opportunities. Guerra previously served as VP of the Americas for Avidity Science. In addition, he has held senior leadership positions with VWR International over the last 14 years. His last role at VWR was VP of sales for the western region of the US. 

Jan 02, 2019

Steve Chapman, Robert Schueren, Matthew Rabinowitz

Natera has appointed Steve Chapman to CEO. He will take over from Matthew Rabinowitz, who will serve as executive chairman, effective Jan. 2, 2019. Chapman was previously the company's chief operating officer and Robert Schueren will replace Chapman as Natera's COO, effective Jan. 7, 2019. Schueren was most recently CEO of IntegenX, which was acquired by Thermo Fisher Scientific. Previously, he was general manager of genomics at Agilent Technologies and has also held various roles at Genentech.

Jan 02, 2019

Peter Meldrum

Myriad Genetics' former CEO Peter Meldrum passed away on Dec. 20, 2018, at the age of 71.


Meldrum co-founded Myriad in 1992 with Mark Skolnick, and led the company through many milestones, including its public offering in 1995, the launch of the flagship BRACAnalysis test, the acquisitions of Myriad RBM and Crescendo Bioscience, and the firm's expansion outside the US. By the time he retired in 2015, Myriad had grown to employ 2,500 people and had performed more than 2 million genetic tests.

After his retirement, Meldrum was the executive director of The Meldrum Foundation, his family's private charitable foundation that supports educational, artistic, and humanitarian programs. He was also chairman of the board of directors for Golden Pine Ventures, a biotech-focused venture capital firm.

Meldrum was born in 1947 in Salt Lake City, Utah. In 1970, he received his Bachelor of Science degree in chemical engineering from the University of Utah, and four years later received his MBA from the same institution. Westminster College awarded him an honorary Doctorate of Science in 2004 and the University of Utah gave him an honorary Doctorate of Engineering degree in 2009. Scientific American in 2002 selected him as one of the Top 50 Scientific Visionaries in the World.

Dec 26, 2018

Brad Wertz

Brad Wertz, chairman and founding investor of GenomOncology, will take over as CEO on Jan. 1, the Cleveland-based company announced. Manuel Glynias, GenomOncology's current CEO and founder, will remain president. Wertz has a history of scaling technology companies in various industries as they move from startup to growth phase, including bioinformatics software maker Acero. 

Dec 18, 2018

Jessica Hassel, Aurélien Marabelle

Protagen has appointed Jessica Hassel and Aurélien Marabelle to the firm's scientific advisory board. The members will support the company in developing and implementing its immuno-profiling technology. Hassel is currently the head of dermato-oncology at Germany's National Center for Tumor Disease. She has worked at the German Cancer Research Center Heidelberg, with a focus on translational oncology. Marabelle is currently the clinical director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. He works as a senior medical oncologist and an investigator in the center's drug development department. 

Dec 17, 2018

Amy Abernethy

Amy Abernethy, current chief medical officer, CSO, and senior VP of oncology at Flatiron Health, will join the US Food and Drug Administration as principal deputy commissioner, second to the agency's commissioner Scott Gottlieb. She is slated to join the agency in early 2019, pending ethics clearances, and will replace Rachel Sherman, who is retiring as the FDA's current principal deputy commissioner. Patrizia Cavazzoni, who is deputy director for operations at the FDA's drug center, will step in as interim principal deputy commissioner till Abernethy joins.

Abernethy became an executive at cancer-focused health technology firm Flatiron more than four years ago. She currently serves as a member of the board for CareDx, and will step down from that post effective Jan. 31, 2019. She has served as a director on the company's board since July 2018 as chairman of the scientific committee. Abernethy has also worked at Athenahealth and directed the Duke Center for Learning Health Care. In an internal email about Abernethy's hire, the FDA highlighted that she is an internationally recognized expert in clinical trials, cancer outcomes research, health policy, patient-reported outcomes, and patient-centered care, and has authored more than 400 peer-reviewed articles.

The non-profit advocacy organization Personalized Medicine Coalition, where Abernethy serves as a board member, noted in a statement that the agency's decision to hire her reflects its increasing focus on personalized medicine. While Abernethy was at Flatiron, the company struck up a research alliance with the FDA to explore how real-world data, derived from sources outside of the traditional clinical trial setting, could be used to gather evidence on the safety and efficacy of cancer treatments.

Dec 17, 2018

Richard Marsh, Benjamin Jackson

Richard Marsh, executive VP of Myriad Genetics, as well as its general counsel and secretary, will retire from the company effective July 1, 2019.  After serving as Myriad's general counsel for more than 16 years, Marsh has acceped the job of mission president for the Church of Jesus Christ of Latter-day Saints for the next three years.

Benjamin Jackson, currently Myriad's VP, assistant general counsel, and assistant secretary, will succeed Marsh. Jackson has been with the company since 2006 and has held positions dealing with commercial operations and intellectual property issues.

Dec 12, 2018

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Melissa Lueke, executive VP and CFO at Meridian Bioscience, will retire from her position effective Jan. 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of corporate development to the position of EVP, CFO, and principal financial officer, also effective Jan. 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior VP, Corporate Controller and Treasurer.

Dec 11, 2018

Catherine Friedman, Alex Aravanis

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She has also held numerous executive positions during her investment banking career with Morgan Stanley, including as managing director and head of West Coast healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as CSO and head of R&D. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of R&D for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

Dec 11, 2018

Hans Clevers

The board of directors of Roche Holding has proposed Hans Clevers as a new board member. He is scheduled to be elected to the board at the company's annual general meeting on March 5, 2019. Clevers is a professor of molecular genetics at the University Medical Center Utrecht in the Netherlands.

Dec 10, 2018

Cynthia Collins

Cynthia Collins has joined the board of directors of Editas Medicine. Most recently, she was the CEO of Human Longevity. Prior to that, she was CEO/GM of General Electric's Healthcare Cell Therapy Business, Lab Businesses, and Clarient Diagnostics. Before that, she was president and CEO of GenVec, and prior to that, group vice president of the Cellular Analysis Business of Beckman Coulter. Collins holds a BS degree in microbiology from the University of Illinois, Urbana, and an MBA from the University of Chicago Booth School of Business.

Dec 10, 2018

Daniel O'Day, William Anderson

Daniel O'Day will leave his post as CEO and corporate executive committee member of Roche Pharmaceuticals at the end of December to become CEO and board chairman of Gilead Sciences, effective March 1, 2019.

In the interim period, he will provide support to Roche to ensure a smooth transition to his successor, William Anderson, who will become CEO of Roche Pharmaceuticals effective Jan. 1, 2019. Anderson currently serves as CEO of Roche-owned Genentech, which he joined in 2006. In previous roles, he led Genentech's immunology business unit, headed oncology sales and marketing, and led global product strategy.

Dec 10, 2018

Prahlad Singh

Prahlad Singh has been appointed president and chief operating officer of PerkinElmer, effective Jan. 1, 2019. Singh will be responsible for the Discovery and analytical solutions and the diagnostics operating divisions. He joined PerkinElmer in 2014 as president of the diagnostics business, was elected as an officer in 2016 and executive vice president in 2016. Prior to joining the firm, Singh served as general manager of GE Healthcare's women's health business. He has also held senior executive level positions in strategy, business development, and M&A at GE and at Philips Healthcare.


Dec 10, 2018

Bradley Cole

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

Dec 07, 2018

E. Robert Wassman

NeuroPointDx, a division of Stemina Biomarker Discovery, has appointed E. Robert Wassman as its medical director. Wassman has acted as chief medical officer (CMO) for several companies in the genetic testing, biomarker discovery, and diagnostic development space. He previously served as CMO of Lineagen from 2015 to 2017. Before that, he served as CMO at Rosetta Genomics from 2012 to 2015. Wassman has also previously served as CMO at other companies in the personalized medicine space over the past 35 years, including Genzyme Genetics, Celula, Ambry Genetics, and Alfigen. 

Dec 07, 2018

Caroline Loew, Stanley Lapidus, Robert Langer

Glympse Bio has appointed Caroline Loew as the firm's president and CEO. Loew previously served as VP, heading of R&D strategy and planning at Bristol-Myers Squibb. In addition, she has served in senior roles at Merck and phRMA over the past 20 years, where she led teams in drug development, regulatory policy, market access, and commercial. 

Glympse has also appointed Stanley Lapidus as the firm's chairman and Robert Langer to the firm's board of directors. Lapidus has been the founding CEO of four medical technology companies, including Cytyc, Exact Sciences, Helicos, and SynapDx.

Dec 06, 2018

Hilde Furberg, Guido Oelkers

Blueprint Genetics has appointed Hilde Furberg as chairman of its board of directors. Furberg previously served as head of rare disease Europe at Sanofi Genzyme. She is also currently an industrial advisor to Investinor and a board member of BerGenBio, Calliditas, and Tappin. Hilde has previously worked at companies including Baxter and Genzyme, and has also been a board member of Probi, Pronova, Clavis, and Algeta.

In addition, Blueprint has appointed Guido Oelkers as a senior advisor to the firm. Oelkers currently serves as CEO of Swedish Orphan Biovitirum. Previously, he served in roles including CEO of BSN Medical, CEO of Gambro, CEO of Invida, and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group, and Aventis. 

Dec 06, 2018

Bradley Cole

Castle Biosciences has appointed Bradley Cole to its board of directors. Cole currently serves as Genomic Health's CFO. In addition, Cole served as both chief operating officer and CFO at the firm. Previously, Cole served as VP of finance and business development for the Endovascular Solutions Group at Guidant. Prior to that, he served as VP and general manager of the vascular surgery business unit of Guidant. Previously, he served as CFO at Endovascular Technologies until it was acquired by Guidant in 1997. Before Endovascular, he served as CFO at Applied Biosystems until 1994. 

Nov 30, 2018

Stevan Knezevich

DermTech has appointed Stevan Knezevich to its scientific advisory board. Knezevich has a PhD in pathology and laboratory medicine from the University of Vancouver, B.C., and a MD from the University of Toronto. 

Nov 28, 2018

Joseph Khoury

Angle has appointed Joseph Khoury to its scientific advisory board. Khoury currently serves as a tenured professor of pathology and laboratory medicine at the University of Texas MD Anderson Cancer Center.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.